A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 12, 2026 54 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Relugolix Approval Expected to Alter Treatment for Advanced Prostate Cancer January 26, 2021 2021 ASCO Annual Meeting Research Round Up: Advances in Treating Lung... August 5, 2021 Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients... June 4, 2025 Holidays and Hope When a Loved One Has Advanced Cancer December 20, 2023 Load more HOT NEWS What People With Cancer Should Know About Immune Checkpoint Inhibitor Side... “White Bagging” Harmful to Patients, Requires Them to Use Insurance-Approved Formulary... ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of... ACHIEVE-2 Results of Oxaliplatin-Based Adjuvant Chemotherapy in Asian Patients with High-Risk...
